Authored Content

A detailed Avalere report offers insights into state-specific statutes guiding commercial payer coverage for off-label use of oncology drugs/biologics.

Avalere’s report, available now, offers insights into state policies on point-of-service substitution of biosimilar products.

Recent FDA authorization of Florida’s Section 804 Importation Program has prompted increased focus on importation pathways.

Receiving a complete response letter is not a rejection, but it introduces important business questions for product launch planning.